Six-week daily rifapentine to prevent TB in people with HIV, young children, and pregnant women
Short-course rifapentine for TB prevention for all: clinical pharmacology matters
This project checks whether six weeks of daily rifapentine safely prevents TB and reaches the right drug levels in people with HIV on dolutegravir, young children, and pregnant women.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11163508 on NIH RePORTER |
What this research studies
If you join, you would take six weeks of daily rifapentine and give a few small blood samples so researchers can measure drug levels. The study will include people with HIV who are taking dolutegravir, children under 12, and pregnant women—groups that were excluded from the main ASTERoiD trial. Researchers will use sparse sampling and population pharmacokinetic methods to confirm that model-based doses achieve target drug exposures and to explore reasons for differences in drug levels between people. Safety and tolerability will be tracked so the shorter preventive regimen is safe for these priority groups.
Who could benefit from this research
Good fit: Ideal candidates are people with HIV taking dolutegravir, children under age 12 at risk for TB infection, and pregnant women eligible for TB preventive therapy.
Not a fit: People with active tuberculosis, those not at risk of TB exposure, or individuals taking medications incompatible with rifapentine may not receive benefit from participation.
Why it matters
Potential benefit: If successful, this could expand a shorter, safe TB-prevention option to people with HIV, young children, and pregnant women by confirming appropriate dosing.
How similar studies have performed: Short rifamycin-based prevention regimens (for example 3HP and 4R) have worked well in many adults, but confirming six-week daily rifapentine dosing in people on dolutegravir, young children, and pregnant women is a new and necessary step.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Dooley, Kelly E. — Vanderbilt University Medical Center
- Study coordinator: Dooley, Kelly E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.